About this Research Topic
This Research Topic is part of a series with Impacts of 2021 WHO Classification on the Precise Diagnosis and Management of Gliomas
The 2021 WHO classification for CNS tumors was released last year. It has been continuously striking our clinical practice and changing our everyday clinical decision-making. Glioma is the most common malignant primary brain tumor. One central aspect is that next-generation sequencing for the resected glioma samples is increasingly becoming a mandate and the molecular diagnosis is more and more being the center for the accurate diagnosis and individualized decision-making for gliomas of all subtypes. However, since this is absolutely a new area, there are still many essential, unsolved clinical problems when using this new classification for gliomas.
In this Research Topic (Impacts of 2021 WHO Classification on the Precise Diagnosis and Management of Gliomas), we aim to address the unsolved clinical problems regarding the introduction of the 2021 WHO classification in gliomas. Focuses of this topic include but not limit to: 1) the real-world distribution of different types of gliomas using the current classification system. 2) the clinical characteristics, molecular features, and prognosis of different types of gliomas using the current classification system. 3) the changes of diagnosis and management of gliomas based on the 2021 WHO classification. The final goal is to better suit the 2021 WHO Classification into the real-world clinical practice on gliomas and improve patient management and prognosis.
This topic welcomes basic, applied, and clinical investigations as they relate to the use of 2021 WHO classification into the field of gliomas. It provides a high-level forum for communication among neurosurgeons, neuropathologists, neurologists, radiotherapists, and laboratory-based oncologists. This section encompasses research related to adult and/or pediatric gliomas. Original articles and review articles are welcome.
The 2021 WHO classification for CNS tumors was released last year. It has been continuously striking our clinical practice and changing our everyday clinical decision-making. Glioma is the most common malignant primary brain tumor. One central aspect is that next-generation sequencing for the resected glioma samples is increasingly becoming a mandate and the molecular diagnosis is more and more being the center for the accurate diagnosis and individualized decision-making for gliomas of all subtypes. However, since this is absolutely a new area, there are still many essential, unsolved clinical problems when using this new classification for gliomas.
In this Research Topic (Impacts of 2021 WHO Classification on the Precise Diagnosis and Management of Gliomas), we aim to address the unsolved clinical problems regarding the introduction of the 2021 WHO classification in gliomas. Focuses of this topic include but not limit to: 1) the real-world distribution of different types of gliomas using the current classification system. 2) the clinical characteristics, molecular features, and prognosis of different types of gliomas using the current classification system. 3) the changes of diagnosis and management of gliomas based on the 2021 WHO classification. The final goal is to better suit the 2021 WHO Classification into the real-world clinical practice on gliomas and improve patient management and prognosis.
This topic welcomes basic, applied, and clinical investigations as they relate to the use of 2021 WHO classification into the field of gliomas. It provides a high-level forum for communication among neurosurgeons, neuropathologists, neurologists, radiotherapists, and laboratory-based oncologists. This section encompasses research related to adult and/or pediatric gliomas. Original articles and review articles are welcome.
Keywords: WHO Classification, diagnosis, management, glioma
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
